104 related articles for article (PubMed ID: 32949087)
21. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
[TBL] [Abstract][Full Text] [Related]
22. Comparing outcomes of concurrent chemotherapy regimens in patients 65 years old or older with locally advanced oropharyngeal carcinoma.
Amini A; Eguchi M; Jones BL; Stokes WA; Gupta A; McDermott JD; Massarelli E; Bradley CJ; Karam SD
Cancer; 2018 Nov; 124(22):4322-4331. PubMed ID: 30291789
[TBL] [Abstract][Full Text] [Related]
23. Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head and neck in the United States.
Aggarwal H; Punekar RS; Li L; Carter GC; Walker MS
Health Qual Life Outcomes; 2020 Jun; 18(1):195. PubMed ID: 32571349
[TBL] [Abstract][Full Text] [Related]
24. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial.
Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI
Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A
Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463
[TBL] [Abstract][Full Text] [Related]
26. High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
Perez CA; Wu X; Amsbaugh MJ; Gosain R; Claudino WM; Yusuf M; Roberts T; Jain D; Jenson A; Khanal S; Silverman CI; Tennant P; Bumpous JM; Dunlap NE; Rai SN; Redman RA
Oral Oncol; 2017 Apr; 67():24-28. PubMed ID: 28351577
[TBL] [Abstract][Full Text] [Related]
27. Predictors of distant metastasis in human papillomavirus-associated oropharyngeal cancer.
Weller MA; Ward MC; Berriochoa C; Reddy CA; Trosman S; Greskovich JF; Nwizu TI; Burkey BB; Adelstein DJ; Koyfman SA
Head Neck; 2017 May; 39(5):940-946. PubMed ID: 28188964
[TBL] [Abstract][Full Text] [Related]
28. Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer.
Strom TJ; Trotti AM; Kish J; Russell JS; Rao NG; McCaffrey J; Padhya TA; Otto KJ; Caudell JJ
Oral Oncol; 2015 Jul; 51(7):704-8. PubMed ID: 25936651
[TBL] [Abstract][Full Text] [Related]
29. Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial.
Tao Y; Auperin A; Sire C; Martin L; Khoury C; Maingon P; Bardet E; Kaminsky MC; Lapeyre M; Chatellier T; Alfonsi M; Pointreau Y; Jadaud E; Géry B; Zawadi A; Tourani JM; Laguerre B; Coutte A; Racadot S; Hasbini A; Malaurie E; Borel C; Meert N; Cornely A; Ollivier N; Casiraghi O; Sun XS; Bourhis J
J Clin Oncol; 2018 Jun; ():JCO2017762518. PubMed ID: 29878867
[TBL] [Abstract][Full Text] [Related]
30. Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
Iganej S; Beard BW; Chen J; Buchschacher GL; Abdalla IA; Thompson LDR; Bhattasali O
Oral Oncol; 2019 Oct; 97():18-22. PubMed ID: 31421466
[TBL] [Abstract][Full Text] [Related]
31. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
32. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zumsteg ZS; Lok BH; Ho AS; Drill E; Zhang Z; Riaz N; Shiao SL; Ma J; McBride SM; Tsai CJ; Baxi SS; Sherman EJ; Lee NY
Cancer; 2017 Apr; 123(8):1345-1353. PubMed ID: 27984656
[TBL] [Abstract][Full Text] [Related]
33. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
[TBL] [Abstract][Full Text] [Related]
34. Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
Samuels SE; Tao Y; Lyden T; Haxer M; Spector M; Malloy KM; Prince ME; Bradford CR; Worden FP; Schipper M; Eisbruch A
Oral Oncol; 2016 Mar; 54():68-74. PubMed ID: 26776757
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial.
Maddalo M; Borghetti P; Tomasini D; Corvò R; Bonomo P; Petrucci A; Paiar F; Lastrucci L; Bonù ML; Greco D; Costa L; Pegurri L; Triggiani L; Belgioia L; Desideri I; Grisanti S; Buglione M; Magrini SM
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):469-477. PubMed ID: 32184121
[TBL] [Abstract][Full Text] [Related]
36. Validation of the 8
van Gysen K; Stevens M; Guo L; Jayamanne D; Veivers D; Wignall A; Pang L; Guminski A; Lee A; Hruby G; Macleod P; Taylor A; Eade T
BMC Cancer; 2019 Jul; 19(1):674. PubMed ID: 31288767
[TBL] [Abstract][Full Text] [Related]
37. Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer.
Xiang M; Colevas AD; Holsinger FC; Le QX; Beadle BM
J Natl Compr Canc Netw; 2019 Sep; 17(9):1065-1073. PubMed ID: 31487677
[TBL] [Abstract][Full Text] [Related]
38. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer.
Tang C; Chan C; Jiang W; Murphy JD; von Eyben R; Colevas AD; Pinto H; Lee-Enriquez N; Kong C; Le QT
Head Neck; 2015 Mar; 37(3):386-92. PubMed ID: 24431011
[TBL] [Abstract][Full Text] [Related]
39. Real-world study of patients with locally advanced HNSCC in the community oncology setting.
Black CM; Ramakrishnan K; Nadler E; Tseng WY; Wentworth C; Murphy J; Fulcher N; Wang L; Alexander M; Patton G
Front Oncol; 2023; 13():1155893. PubMed ID: 37664029
[TBL] [Abstract][Full Text] [Related]
40. Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial.
Geoffrois L; Martin L; De Raucourt D; Sun XS; Tao Y; Maingon P; Buffet J; Pointreau Y; Sire C; Tuchais C; Babin E; Coutte A; Rolland F; Kaminsky MC; Alfonsi M; Lapeyre M; Saliou M; Lafond C; Jadaud E; Gery B; Zawadi A; Tourani JM; Khoury C; Henry AR; Hasbini A; Guichard F; Borel C; Meert N; Guillet P; Calais MH; Garaud P; Bourhis J
J Clin Oncol; 2018 Nov; 36(31):3077-3083. PubMed ID: 30016178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
